HDL-C: what your result means.

HDL cholesterol (HDL-C) is the cholesterol carried in high-density lipoprotein particles, which transport cholesterol away from tissues back to the liver. Low HDL is one of the most consistent markers of elevated cardiovascular and metabolic risk.

Why HDL-C matters

HDL illustrates why evidence-based interpretation matters: low HDL robustly predicts risk, yet trials and genetic studies show that artificially raising HDL does not reduce events. HDL is a marker, not a target. A low value points to the underlying metabolic dysfunction (insulin resistance, high triglycerides) that deserves the attention.

Associated risks when out of range: Higher cardiometabolic risk when low. Increased coronary artery disease risk at very low levels. Paradoxically elevated all-cause mortality when very high (>2.3 mmol/L).

What the clinical evidence shows

The evidence base behind how the HodieLabs Evidence-Based Clinical Library interprets HDL-C, from randomised trials, prospective cohorts and genetic (Mendelian randomisation) studies. Full citations in the reference list below.

• Framingham Heart Study (Gordon et al. American Journal of Medicine 1977): the original demonstration that low HDL is a powerful independent predictor of coronary heart disease, an inverse association replicated in essentially every major cohort since.
• Mendelian randomisation analysis (Voight et al. The Lancet 2012): genetic variants that raise HDL lifelong do not reduce heart attack risk, pivotal evidence that HDL marks risk rather than causing protection.
• ILLUMINATE trial (Barter et al. NEJM 2007): torcetrapib raised HDL by 72% yet increased cardiovascular events and mortality, the definitive trial lesson that treating the HDL number, rather than the underlying metabolic health, fails.

Evidence-based reference ranges

The HodieLabs Evidence-Based Clinical Library interprets HDL-C against published clinical authority standards, never arbitrary "optimal" ranges. Measured in mmol/L:

Clinical interpretation

• HDL function (cholesterol efflux capacity) matters more than absolute level.
• Focus on TG/insulin/ApoB context rather than trying to pharmacologically raise HDL.
• Very high HDL (>2.3 mmol/L) is not necessarily protective and may reflect dysfunctional particles or CETP deficiency. Investigate if persistent.
• Interpret alongside TG/HDL ratio, ApoB, and insulin for full atherogenic picture.
• Exercise is the most evidence-based intervention for raising functional HDL.

What improves it: the evidence-based levers

• Increase aerobic physical activity (strongest HDL raiser)
• Improve insulin sensitivity
• Weight optimisation (especially visceral fat reduction)
• Moderate alcohol intake (if applicable)
• Smoking cessation (if applicable)

Recommended testing frequency: Annual, as part of a comprehensive panel. Single markers are always interpreted in context.

How HDL-C testing works at HodieLabs

HDL-C is measured in every Health Blueprint at our Melbourne Preventative Health & Longevity Clinic, interpreted by a doctor against the guideline-cited ranges above and tracked over time through your HodieLabs membership.

References

1. Gordon T, et al. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med. 1977;62:707–714.
2. Voight BF, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380:572–580.
3. Barter PJ, et al. Effects of torcetrapib in patients at high risk for coronary events (ILLUMINATE). N Engl J Med. 2007;357:2109–2122.

This page is general information from the HodieLabs Evidence-Based Clinical Library, not medical advice. Speak with your GP about what testing and care is appropriate for you.